Savara (NASDAQ:SVRA) Price Target Raised to $8.00

Savara (NASDAQ:SVRA) had its price objective boosted by HC Wainwright from $5.00 to $8.00 in a research note released on Wednesday, Marketbeat Ratings reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Savara’s FY2026 earnings at ($0.38) EPS, FY2027 earnings at ($0.17) EPS, FY2028 earnings at $0.11 EPS and FY2029 earnings at $0.50 EPS.

SVRA has been the topic of several other reports. Oppenheimer raised their price target on Savara from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, August 15th. Evercore ISI dropped their price objective on Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a report on Wednesday, May 28th. Wells Fargo & Company dropped their price objective on Savara from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Wednesday, May 28th. Finally, Guggenheim reiterated a “buy” rating and issued a $8.00 price objective (down previously from $9.00) on shares of Savara in a report on Wednesday, May 28th. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat.com, Savara presently has an average rating of “Moderate Buy” and an average price target of $6.67.

Savara Price Performance

SVRA opened at $3.72 on Wednesday. The stock’s 50 day simple moving average is $2.71 and its 200 day simple moving average is $2.71. The company has a debt-to-equity ratio of 0.25, a current ratio of 11.08 and a quick ratio of 11.08. Savara has a 1 year low of $1.89 and a 1 year high of $4.70. The firm has a market cap of $642.96 million, a price-to-earnings ratio of -7.44 and a beta of 0.56.

Savara (NASDAQ:SVRA) last posted its quarterly earnings results on Wednesday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, analysts predict that Savara will post -0.45 earnings per share for the current year.

Insider Activity at Savara

In other news, Director Richard J. Hawkins bought 48,225 shares of the stock in a transaction dated Friday, June 20th. The stock was bought at an average price of $2.04 per share, for a total transaction of $98,379.00. Following the purchase, the director directly owned 115,466 shares in the company, valued at $235,550.64. This trade represents a 71.72% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.33% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the company. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in shares of Savara by 24.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 156,983 shares of the company’s stock valued at $482,000 after purchasing an additional 31,168 shares during the period. Millennium Management LLC lifted its stake in shares of Savara by 71.8% in the 4th quarter. Millennium Management LLC now owns 482,263 shares of the company’s stock valued at $1,481,000 after purchasing an additional 201,599 shares during the period. Deutsche Bank AG lifted its stake in shares of Savara by 6.1% in the 4th quarter. Deutsche Bank AG now owns 927,595 shares of the company’s stock valued at $2,848,000 after purchasing an additional 53,054 shares during the period. D. E. Shaw & Co. Inc. lifted its stake in shares of Savara by 314.7% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 70,560 shares of the company’s stock valued at $217,000 after purchasing an additional 53,547 shares during the period. Finally, Farther Finance Advisors LLC lifted its stake in shares of Savara by 25.3% in the 1st quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company’s stock valued at $92,000 after purchasing an additional 6,532 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.